Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-25T15:01:11.953Z Has data issue: false hasContentIssue false
  • English
  • Français

Propranolol in Chronic Schizophrenia: A Controlled Study in Neuroleptic-Treated Patients

Published online by Cambridge University Press:  29 January 2018

Leif H. Lindström  and
Eva Persson
Leif H. Lindström
Affiliation:
Psychiatric Research Center, Ulleraker Hospital, S–750 17 Uppsala, Sweden
Eva Persson
Affiliation:
Psychiatric Research Center, Ulleraker Hospital, S–750 17 Uppsala, Sweden
Get access Rights & Permissions [Opens in a new window]

Abstract

The effect of propranolol at a dose level of 1,280–1,920 mg per day was studied with a double-blind crossover design in twelve chronic schizophrenics with persistent psychotic symptoms despite maintenance treatment with a depot neuroleptic. By use of a psychiatric rating scale (CPRS), an improvement was seen during the two week period of propranolol compared to placebo treatment in six patients, whereas three patients were unchanged and three deteriorated. The effect on total symptom scores for the whole group was significantly better after propranolol. The data indicate that propranolol in high doses has an antipsychotic effect in some schizophrenic patients when receiving neuroleptics.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 137 , Issue 2 , August 1980 , pp. 126 - 130
Copyright
Copyright © Royal College of Psychiatrists, 1980 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Åsberg, M., Montgomery, S. A., Perris, C., Schalling, D. & Sedvall, G. (1978) A comprehensive psycho-pathological rating scale. Acta Psychiatrica Scandinavica, Supplement 271, 1–62.Google Scholar
Atsmon, A. & Blum, I. (1970) Treatment of acute porphyria variegata with propranolol. Lancet, i, 196–97.CrossRefGoogle Scholar
Atsmon, A. & Blum, I., Wijsenbeek, H., Maoz, B., Steiner, M. & Ziegelman, G. (1971) The short-term effects of adrenergic-blocking agents in a small group of psychotic patients. Psychiatria Neurologia Neurochirurgia, 74, 251–8.Google Scholar
Atsmon, A. & Blum, I., Steiner, M., Latz, A. & Wijsenbeek, H. (1972) Further studies with propranolol in psychotic patients. Psychopharmacologia (Berlin), 27, 249–54.Google Scholar
Elizure, A., Segal, Z., Yeret, A., Davidson, S. & Ben-David, M. (1978) Antipsychotic activity and mode of action of propranolol vs. neuroleptic drugs. Israel Journal of Medical Science 14 (4), 493–4.Google Scholar
Gardos, G., Cole, J. O., Volicer, L., Orzack, M. H. & Cole Oliff, A. (1973) A dose-response study of propranolol in chronic schizophrenics. Current Therapeutic Research, 15, 314–23.Google Scholar
Hanssen, T., Heyden, T., Sundberg, I., Alfredsson, G., Nybäck, H. & Wetterberg, L. (1978) Propranololbehandling vid schizofreni. Nordisk Psykiatrisk Tidsskrift, 32, 393–400.Google Scholar
Laverty, R. & Taylor, K. M. (1968) Propranolol uptake into the central nervous system and the effect on rat behavior and amine metabolism. Journal of Pharmacy and Pharmacology, 20, 605–9.Google Scholar
Lloyd, M. E. & Whitehead, J. S. (1976) Development and evaluation of behaviorally taught practice. In Teaching Behavior Modification (eds. Yen, S. and McIntyre, R. W.). Kalamazoo: Behaviordelia.Google Scholar
Sheppard, G. P. (1979) High-dose propranolol in schizophrenia. British Journal of Psychiatry, 134, 470–76.Google Scholar
Turner, P., Granville-Grossman, K. L. & Smart, J. V. (1965) Effect of adrenergic receptor blockade on the tachycardia of thyrotoxicosis and anxiety state. Lancet, ii, 1316–18.Google Scholar
Turner, P. & Lader, M. H. (1974) Response to propranolol and diazepam in somatic anxiety and psychic anxiety. British Medical Journal, ii, 15–16.Google Scholar
van Zerssen, D. (1976) Beta-adrenergic blocking agents in the treatment of psychoses. A report on 17 cases. Advances in Clinical Pharmacology, 12, 105–14.Google Scholar
Wheatley, D. (1969) Comparative effects of propranolol and chlordiazepoxide in anxiety states. British Journal of Psychiatry, 115, 1411–12. Yorkstone, N. J., Zaki, S. A., Themen, J. F. A.&Google Scholar
Havard, C. W. H. (1976) Propranolol to control schizophrenic symptoms: 55 patients. Advances in Clinical Pharmacology, 12, 91–104.Google Scholar
Havard, C. W. H., Gruzelier, J. H., Zaki, S. A., Hollander, D., Pitcher, D. R. & Sergeant, H. G. S. (1977) Propranolol as an adjunct to the treatment of schizophrenia. Lancet, ii, 575–78.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.